Primary liver cancer
Conditions
Interventions
Case series:Autologous RAK cells
Sponsors
Cancer Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old; 2. Patients with primary liver cancer were confirmed by histological examination; 3. No other combination treatment before and after operation (radiotherapy, chemotherapy, etc., except traditional Chinese medicine); In addition, if one of the following conditions is met, the group can be enrolled: 1) tumor greater than or equal to 5cm or involved/located in the middle of the liver or adjacent to the tumor ( 20ng/mL; 7) positive lymph nodes; 4. Effective methods of contraception from screening to the end of the trial should be agreed upon for women and men who are fertile; 5. Sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who had received cytotoxic chemotherapy within 3 months, patients who had received targeted drug therapy within 2 months, patients who had received interferon and/or interleukin-2 within 3 months;I have received targeted drugs for immune nodes; 3. Have used immunosuppressive agents (including azathioprine, 6-mp, cyclosporin, tisirolimus, ivermox, rapamycin, etc.); Long-term use of corticosteroids; 4. Has previously been treated with dc-cik or CIK cells, autologous RAK/LAK cells or other adoptive immunotherapy; 5. Has a history of other malignant diseases in the last five years (with the exception of cured skin cancer and cervical carcinoma in situ).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| total survival; | — |
Countries
China
Contacts
Public ContactJie Ma
Beijing Hospital
Outcome results
None listed